|
Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). |
|
|
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Precision Biosciences; Takeda |
Speakers' Bureau - Celgene; Karyopharm Therapeutics |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson; Pfizer |
Consulting or Advisory Role - Agios; Amgen; AstraZeneca; Incyte; Novartis; Ono Pharmaceutical |
Speakers' Bureau - Agios; Amgen; Celgene; Gilead Sciences; Incyte; Sanofi; Stemline Therapeutics |
Research Funding - Abbvie; Actinium Medical Advisory Board; Agios; Amgen; ARIAD; Astellas Oncology; Bristol-Myers Squibb; Celator; Constellation Pharmaceuticals; Cyclacel; Daiichi Sankyo; Deciphera; Delta-Fly Pharma |
Expert Testimony - Kaiser Permanente |
|
|
Research Funding - Cellectar |
|
|
Honoraria - Alnylam; Caelum Biosciences; Caelum Biosciences; Celgene (I); Genzyme; Karyopharm Therapeutics; Oncopeptides |
Speakers' Bureau - Celgene |
Research Funding - Amgen (Inst); Celgene (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Roche (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Celgene; Karyopharm Therapeutics |
|
|
Honoraria - Abbvie; Amgen; Celgene; Janssen; Karyopharm Therapeutics; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi; Takeda |
Research Funding - Celgene; Janssen |
|
|
Honoraria - Amgen; Antengene; Celgene; Janssen; Karyopharm Therapeutics; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Antengene; Celgene; Janssen; Karyopharm Therapeutics; Sanofi; Takeda |
|
|
Honoraria - Abbvie; Amgen; AstraZeneca; Celgene; Janssen |
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Celgene; Janssen |
Research Funding - Celgene; Sanofi |
|
|
Honoraria - Alphasights; Cardinal Health; Gerson Lehrman Group; Guidepoint Global; NCCN/Boehringer Ingelheim; Olson Research Group; Putnam Associates |
Consulting or Advisory Role - Celgene; Karyopharm Therapeutics |
Travel, Accommodations, Expenses - Cardinal Health; Celgene; Karyopharm Therapeutics; NCCN/Boehringer Ingelheim |
|
|
Honoraria - Amgen; Celgene; Janssen-Ortho |
Consulting or Advisory Role - Amgen; Celgene; Janssen-Ortho |
Research Funding - GlaxoSmithKline (Inst); Janssen-Ortho (Inst); Karyopharm Therapeutics (Inst) |
|
|
Stock and Other Ownership Interests - Karyopharm Therapeutics |
Honoraria - Amgen; Celgene; Janssen; Merck; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen; Merck; Takeda |
Research Funding - Merck; Sanofi; Takeda |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Ortho; Karyopharm Therapeutics; Takeda |
Research Funding - Janssen |
Patents, Royalties, Other Intellectual Property - Patent but with no associated royalties or profit |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen; Sanofi |
|
|
Honoraria - Amgen; Celgene; Johnson & Johnson; Sanofi; Takeda |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen |
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Celgene; Janssen |
|
|
Employment - Karyopharm Therapeutics |
Stock and Other Ownership Interests - Karyopharm Therapeutics |
|
|
Employment - Karyopharm Therapeutics |
Leadership - Karyopharm Therapeutics |
Stock and Other Ownership Interests - Karyopharm Therapeutics |
Other Relationship - Karyopharm Therapeutics |
|
|
Employment - Karyopharm Therapeutics |
Stock and Other Ownership Interests - Karyopharm Therapeutics |
Travel, Accommodations, Expenses - Karyopharm Therapeutics |
|
|
Consulting or Advisory Role - Amgen; celgene; GlaxoSmithKline |
Research Funding - Amgen (Inst); Celgene (Inst); cellectar (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Seagen (Inst) |